Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

JAMA neurology·2026

Same author

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

Same author

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.

Neurology and therapy·2026

Same author

ALSUntangled #82: N-acetylcysteine.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026

Same author

Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.

Advances in therapy·2026

Same author

Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Clinical decision support improves autoimmune/paraneoplastic antibody panel utilization.

Robert D Nerenz¹, Sam I Hooshmand², Eric Jackowiak²

¹Department of Pathology and Laboratory Medicine, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, US.

American Journal of Clinical Pathology

|September 10, 2024

Summary

Clinical decision support tools significantly improved autoimmune and paraneoplastic antibody panel utilization by reducing unnecessary tests and duplicate orders. This enhances diagnostic efficiency and positivity rates for neural-specific antibodies.

Keywords:

antibody panel autoimmune clinical decision support encephalopathy epilepsy neuroimmunology paraneoplastic

More Related Videos

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Related Experiment Videos

Last Updated: Jun 13, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Area of Science:

Clinical diagnostics
Medical informatics
Immunology

Background:

Autoimmune and paraneoplastic antibody panel selection is complex for healthcare professionals.
Lack of familiarity leads to inappropriate test use, increased costs, and delayed diagnoses.

Purpose of the Study:

To assess the impact of order-entry clinical decision support on autoimmune/paraneoplastic antibody panel utilization.
To determine if decision support improves test selection and reduces unnecessary orders.

Main Methods:

Implemented an order-entry clinical decision support tool within an electronic health record system.
The tool guided test selection based on clinical presentation and included duplicate order checking.
Compared ordering practices 12 months pre-implementation and 6 months post-implementation.

Main Results:

Monthly test volume decreased significantly from 75.8 to 54.5 orderables per month.
Duplicate panel orders reduced from 7.0 to 1.2 per month.
Neural-specific antibody positivity rate increased from 4.2% to 6.8% due to reduced overall testing.

Conclusions:

Order-entry clinical decision support is an effective strategy for optimizing autoimmune/paraneoplastic antibody panel utilization.
This approach improves efficiency and diagnostic accuracy in clinical practice.